---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-235819"
form_type: "8-K"
ticker: "AGEN"
cik: "0001098972"
company_name: "AGENUS INC"
filed_at: "2025-10-09T23:59:59+00:00"
generated_at: "2026-05-17T04:09:14.057147+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Agenus enters $10M promissory note with Zydus; bears 3.81% interest, secured by 822,910 INKT shares

## Summary
- Up to $10M note at 3.81% p.a.; matures at APA/SPA closing or 10 days after notification that closing will not occur.
- Proceeds fund Q4 2025 operational expenses of Emeryville and Berkeley facilities; forgiven if APA/SPA closes.
- Collateral: 822,910 shares of MiNK Therapeutics (NASDAQ: INKT); control agreement provides Zydus rights upon default.
- Bridge financing tied to pending Zydus asset purchase; facility expense amounts forgiven if deal closes.

## SEC filing metadata
- accession: 0001193125-25-235819
- form_type: 8-K
- ticker: AGEN
- cik: 0001098972
- company_name: AGENUS INC
- filed_at: 2025-10-09T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1098972/000119312525235819/0001193125-25-235819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1098972/000119312525235819/agen-20251008.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-235819
- JSON: https://secwatch.observer/filing/0001193125-25-235819.json
- Plain text: https://secwatch.observer/filing/0001193125-25-235819.txt

## Key facts
- Debt Financings
  AGENUS INC incurred loan of up to $10,000,000 with Zydus Pharmaceuticals (USA) Inc. at 3.81% per annum maturing matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025, or, if such closings will.
  - Instrument: loan
  - Principal: up to $10,000,000
  - Counterparty: Zydus Pharmaceuticals (USA) Inc.
  - Rate: 3.81% per annum
  - Maturity: matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025, or, if such closings will
  - Event: incurrence
  source text: On October 8, 2025, Agenus Inc. (“Agenus”) entered into a Promissory Note Agreement (the “Note”) with Zydus Pharmaceuticals (USA) Inc. (“Zydus”), a wholly owned subsidiary of Zydus Lifesciences Limited, for up to $10,000,000 (the “Principal Amount”). The Note bears interest at 3.81% per annum and matures upon the closing of the Asset Purchase Agreement and Securities Purchase Agreement signed by Agenus and Zydus on June 3, 2025 (together, the “APA/SPA”), or, if such closings will not occur, within 10 days after notification that the APA/SPA closings will not be consummated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1098972/000119312525235819/0001193125-25-235819-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.